130 related articles for article (PubMed ID: 3459938)
1. The influence of high-dose methotrexate therapy on serum iron.
Schalhorn A; Wilmanns W; Koczorek GE
Klin Wochenschr; 1986 May; 64(10):475-80. PubMed ID: 3459938
[TBL] [Abstract][Full Text] [Related]
2. Ferrokinetics after high-dose methotrexate therapy.
Schalhorn A; Sauer H; Wilmanns W; Stupp-Poutot G
Klin Wochenschr; 1981 Oct; 59(19):1109-13. PubMed ID: 6285071
[TBL] [Abstract][Full Text] [Related]
3. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate clearance and clinical toxicity in osteosarcoma following high-dose methotrexate therapy.
Iqbal MP; Khursheed M; Mahboobali N
J Pak Med Assoc; 1989 Feb; 39(2):38-42. PubMed ID: 2499702
[TBL] [Abstract][Full Text] [Related]
5. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.
Hegyi M; Gulácsi A; Cságoly E; Csordás K; Eipel OT; Erdélyi DJ; Müller J; Nemes K; Lautner-Csorba O; Kovács GT
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1697-702. PubMed ID: 22652833
[TBL] [Abstract][Full Text] [Related]
6. [Serum methotrexate determination by microbiological assay in patients receiving high-dosage methotrexate (author's transl)].
Krisch K; Kotz D; Mehta BM
Wien Klin Wochenschr; 1977 Jul; 89(14):479-81. PubMed ID: 268729
[TBL] [Abstract][Full Text] [Related]
7. [Potential marker of the pharmacodynamic effect of high doses of methotrexate--homocysteine].
Strizhevskaya AM; Senzhapova ER; Dzamraev AZ; Baykova VN
Patol Fiziol Eksp Ter; 2014; (2):40-4. PubMed ID: 25318162
[TBL] [Abstract][Full Text] [Related]
8. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma.
Bacci G; Loro L; Longhi A; Bertoni F; Bacchini P; Versari M; Picci P; Serra M
Anticancer Drugs; 2006 Apr; 17(4):411-5. PubMed ID: 16549998
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs.
Bacci G; Ferrari S; Picci P; Zolezzi C; Gherlinzoni F; Iantorno D; Cazzola A
J Chemother; 1996 Dec; 8(6):472-8. PubMed ID: 8981189
[TBL] [Abstract][Full Text] [Related]
10. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study.
Saeter G; Alvegård TA; Elomaa I; Stenwig AE; Holmström T; Solheim OP
J Clin Oncol; 1991 Oct; 9(10):1766-75. PubMed ID: 1717666
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate for osteosarcoma: toxicity and clinical results.
Breithaupt H; Küenzlen E
Oncology; 1983; 40(2):85-9. PubMed ID: 6600827
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma.
Delepine N; Delepine G; Cornille H; Brion F; Arnaud P; Desbois JC
Anticancer Res; 1995; 15(2):489-94. PubMed ID: 7763028
[TBL] [Abstract][Full Text] [Related]
13. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
[TBL] [Abstract][Full Text] [Related]
14. [A device for rapid elevation of plasma methotrexate (MTX) concentration and its maintenance in high-dose MTX therapy].
Miyauchi Y; Mii Y; Morishita T; Miura S; Honoki K; Aoki M; Kido A; Tamai S; Hino M; Nomura Y; Nakanishi E
Gan To Kagaku Ryoho; 1996 Apr; 23(5):595-9. PubMed ID: 8678518
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate levels and outcome in osteosarcoma.
Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of methotrexate by the ligand-binding assay after "high-dose" therapy for osteosarcoma.
Roberts D; Kidd W; Pratt CB; Peck C; Grinnel J
Cancer; 1979 Sep; 44(3):881-90. PubMed ID: 314328
[TBL] [Abstract][Full Text] [Related]
17. Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma.
Shamberger RC; Rosenberg SA; Seipp CA; Sherins RJ
Cancer Treat Rep; 1981; 65(9-10):739-46. PubMed ID: 6791818
[TBL] [Abstract][Full Text] [Related]
18. Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.
Kiu MC; Liaw CC; Yang TS; Lai GM; Hsi SN; Lu CS
Anticancer Drugs; 1994 Aug; 5(4):480-2. PubMed ID: 7949255
[TBL] [Abstract][Full Text] [Related]
19. [Compatibility and toxicity of methotrexate in the treatment of bone tumors].
Pongracz N; Kelaridis T; Ritschl P
Arzneimittelforschung; 1987 Apr; 37(4):456-60. PubMed ID: 3496891
[TBL] [Abstract][Full Text] [Related]
20. [Immune complex formation and complement changes in osteosarcoma patients treated with high-dose methotrexate].
Körholz D; Körholz U; Jürgens H; Göbel U; Wahn V
Klin Padiatr; 1987; 199(1):22-6. PubMed ID: 2951556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
